166 related articles for article (PubMed ID: 4017163)
1. A phase I and pharmacokinetic comparison of hepatic arterial and peripheral vein infusions of bisantrene for liver cancer.
Weiss GR; Hersh M; Kuhn JG; Ludden TM; von Hoff DD; Kisner DL; Pirtle TE
Cancer Chemother Pharmacol; 1985; 15(2):144-8. PubMed ID: 4017163
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacokinetic analyses of intra-arterial and intra-portal chemotherapeutic agent infusion].
Terashima M; Takagane A; Ikeda K; Abe K; Araya M; Nishizuka S; Yonezawa H; Irinoda T; Saito K
Gan To Kagaku Ryoho; 1996 Sep; 23(11):1499-501. PubMed ID: 8854789
[TBL] [Abstract][Full Text] [Related]
3. Percutaneous hepatic vein isolation and high-dose hepatic arterial infusion chemotherapy for unresectable liver tumors.
Ravikumar TS; Pizzorno G; Bodden W; Marsh J; Strair R; Pollack J; Hendler R; Hanna J; D'Andrea E
J Clin Oncol; 1994 Dec; 12(12):2723-36. PubMed ID: 7989950
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of intraarterial mitomycin C in humans.
Hu E; Howell SB
Cancer Res; 1983 Sep; 43(9):4474-7. PubMed ID: 6409404
[TBL] [Abstract][Full Text] [Related]
5. Augmentation of hepatic doxorubicin extraction with extracorporeal filtration avoids the dose-dependent, nonlinear increase in AUC observed with systemic administration.
Sturgill MG; Brenner DE; August DA
Cancer Chemother Pharmacol; 1998; 41(3):193-200. PubMed ID: 9443635
[TBL] [Abstract][Full Text] [Related]
6. Regional pharmacokinetics of doxorubicin following hepatic arterial and portal venous administration: evaluation with hepatic venous isolation and charcoal hemoperfusion.
Iwasaki T; Ku Y; Kusunoki N; Tominaga M; Fukumoto T; Muramatsu S; Kuroda Y
Cancer Res; 1998 Aug; 58(15):3339-43. PubMed ID: 9699664
[TBL] [Abstract][Full Text] [Related]
7. Phase II evaluation of bisantrene hydrochloride in refractory malignant melanoma. A Southwest Oncology Group Study.
Alberts DS; Mason-Liddil N; Green SJ; Cowan JD; Fletcher WS; Neilan B; Guy JT; Epstein RB
Invest New Drugs; 1987; 5(3):289-92. PubMed ID: 3667164
[TBL] [Abstract][Full Text] [Related]
8. Characterization of the pharmacokinetics of bisantrene (NSC-337766).
Kuhn JG; Ludden TM; Myers JW; Von Hoff DD
Invest New Drugs; 1983; 1(3):253-7. PubMed ID: 6678875
[TBL] [Abstract][Full Text] [Related]
9. Phase I clinical and pharmacokinetic study of bisantrene in refractory pediatric solid tumors.
Pratt CB; Sinkule JA; Etcubanas E; Douglass EC; Crom DB; Choi K; Avery L
Invest New Drugs; 1986; 4(2):149-53. PubMed ID: 3733375
[TBL] [Abstract][Full Text] [Related]
10. A phase I-II trial of mitoxantrone by hepatic arterial infusion in patients with hepatocellular carcinoma or colorectal carcinoma metastatic to the liver.
Jones DV; Patt YZ; Ajani JA; Abbruzzese J; Carrasco CH; Charnsangavej C; Levin B; Wallace S
Cancer; 1993 Nov; 72(9):2560-3. PubMed ID: 8402476
[TBL] [Abstract][Full Text] [Related]
11. Intra-arterial infusion chemotherapy on unresectable hepatocellular carcinoma under occlusion of hepatic arterial flow.
Une Y; Uchino J; Yasuhara M; Misawa K; Kamiyama T; Shimamura T; Sato N; Nakajima Y; Hata Y
Clin Ther; 1993; 15(2):347-54. PubMed ID: 8390917
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical and pharmacokinetic study of leucovorin and infusional hepatic arterial fluorouracil.
Kerr DJ; Ledermann JA; McArdle CS; Buckels J; Neoptolemos J; Seymour M; Doughty J; Budden J; Taylor I
J Clin Oncol; 1995 Dec; 13(12):2968-72. PubMed ID: 8523062
[TBL] [Abstract][Full Text] [Related]
13. Lattice intrahepatic doxorubicin with and without in-flow occlusion: a pharmacokinetic study of direct liver injection.
Averbach A; Stuart OA; Chang D; Sugarbaker PH
Eur J Surg Oncol; 2000 Feb; 26(1):73-9. PubMed ID: 10718184
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacology of hepatic arterial infusions of 5-bromo-2'-deoxyuridine.
Ensminger WD; Walker SC; Stetson PL; Wagner JG; Knol JA; Lawrence TS; Andrews JC
Cancer Res; 1994 Apr; 54(8):2121-4. PubMed ID: 8174116
[TBL] [Abstract][Full Text] [Related]
15. Alternating hepatic arterial infusion and systemic chemotherapy for liver metastases from colorectal cancer: a phase II trial using intermittent percutaneous hepatic arterial access.
Copur MS; Capadano M; Lynch J; Goertzen T; McCowan T; Brand R; Tempero M
J Clin Oncol; 2001 May; 19(9):2404-12. PubMed ID: 11331319
[TBL] [Abstract][Full Text] [Related]
16. Steady-state nonlinear pharmacokinetics of 5-fluorouracil during hepatic arterial and intravenous infusions in cancer patients.
Wagner JG; Gyves JW; Stetson PL; Walker-Andrews SC; Wollner IS; Cochran MK; Ensminger WD
Cancer Res; 1986 Mar; 46(3):1499-506. PubMed ID: 3943107
[TBL] [Abstract][Full Text] [Related]
17. Extrahepatic biliary stenoses after hepatic arterial infusion (HAI) of floxuridine (FUdR) for liver metastases from colorectal cancer.
Aldrighetti L; Arru M; Ronzoni M; Salvioni M; Villa E; Ferla G
Hepatogastroenterology; 2001; 48(41):1302-7. PubMed ID: 11677951
[TBL] [Abstract][Full Text] [Related]
18. Significance of duplex/colour Doppler sonography in hepatic arterial chemotherapy for patients with liver metastases from colorectal carcinoma.
Guadagni S; Pizzutilli A; Mancini E; Varrone A; Palumbo G; Amicucci G; Perri S; Deraco M; Fiorentini G
Eur J Surg Oncol; 2000 Jun; 26(4):381-6. PubMed ID: 10873360
[TBL] [Abstract][Full Text] [Related]
19. Hepatic artery infusion using oxaliplatin in combination with 5-fluorouracil, folinic acid and mitomycin C: oxaliplatin pharmacokinetics and feasibility.
Guthoff I; Lotspeich E; Fester C; Wallin I; Schatz M; Ehrsson H; Kornmann M
Anticancer Res; 2003; 23(6D):5203-8. PubMed ID: 14981990
[TBL] [Abstract][Full Text] [Related]
20. Percutaneous hepatic arterial infusion (HAI) of mitomycin C and floxuridine (FUDR): an effective treatment for metastatic colorectal carcinoma in the liver.
Patt YZ; Mavligit GM; Chuang VP; Wallace S; Johnston S; Benjamin RS; Valdivieso M; Hersh EM
Cancer; 1980 Jul; 46(2):261-5. PubMed ID: 6446376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
